JYNNEOS Vaccine Distribution by Jurisdiction
The Administration for Strategic Preparedness and Response (ASPR) is making JYNNEOS, an FDA-licensed vaccine indicated for prevention of smallpox and mpox (formerly known as monkeypox), available from the Strategic National Stockpile (SNS) to Health Resources and Services Administration (HRSA)-funded health centers and Ryan White HIV/AIDS Program Part C and D clinics. This joint ASPR/HRSA program is an opportunity to work with clinic teams to provide life-saving vaccine doses to individuals who cannot otherwise afford to get them.
The SNS has a limited supply of JYNNEOS doses that expire on October 31, 2024. These vaccines are intended for people who are at high risk of mpox disease and who do not have health care coverage to pay for the vaccines. For additional information: HRSA HIV/AIDS Bureau Update: Special Bulletin | HIV.gov.
To date, the SNS has distributed over one million vials of the JYNNEOS vaccine and over 40,000 treatment courses of TPOXX, TEMBEXA, and VIG-IV in response to the ongoing mpox outbreak in the United States.
On April 1, 2024, Bavarian Nordic commercially launched the JYNNEOS vaccine. During the period immediately following commercialization, HHS has continued to make JYNNEOS vaccine available as needed. The HHS-provided JYNNEOS is intended only as a supplemental supply while commercial availability ramps up, to support access in circumstances in which commercial product is not yet accessible.
On June 28, 2022, HHS announced an enhanced nationwide vaccination strategy to mitigate the spread of mpox. That strategy described vaccination for people who are at risk for mpox infection. Under this strategy, agencies of HHS, including ASPR, the Centers for Disease Control and Prevention, and the U.S. Food and Drug Administration (FDA), collaborated to rapidly expand access to hundreds of thousands of doses of the JYNNEOS vaccine from the SNS for prophylactic use against mpox. These efforts have allowed HHS to distribute vaccines more quickly and equitably to jurisdictions across the country.
HHS declared mpox a public health emergency (PHE) on August 4, 2022. The PHE declaration brought expanded authorities that facilitated a more robust HHS response to the spreading mpox outbreak. Although the PHE expired on January 31, 2023, HHS remains committed to ensuring JYNNEOS vaccine is available to people in the United States who may be exposed, or at risk for exposure, to mpox to prevent or minimize a resurgence in domestic mpox cases, including during the transition of JYNNEOS to the commercial market.
The HHS Mpox Vaccine Operational Planning Guide will continue to be updated as additional information becomes available.
